Factor V Leiden (FVL) and prothrombin G20210A (PTG) mutations and risk of thromboembolic events (TE) in NSABP P-1, the breast cancer prevention trial (BCPT).

被引：0
|
作者：
Garber, JE
Costantino, JP
Wickerham, DL
Berliner, N
Wolmark, N
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Pittsburgh, Allegheny Gen Hosp, Pittsburgh, PA USA
[3] Yale Univ, Sch Med, New Haven, CT USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2002年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
413
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 28 条
  • [1] Factor V Leiden and prothrombin G20210A mutations and the risk of atherothrombotic events in systemic lupus erythematosus
    Pullmann, R
    Skerenová, M
    Lukác, J
    Hybenová, J
    Melus, V
    Kubisz, P
    Rovensky, J
    Pullmann, R
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2004, 10 (03) : 233 - 238
  • [2] Effect of Factor v Leiden and prothrombin G20210→A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial
    Abramson, Neil
    Costantino, Joseph R.
    Garber, Judy E.
    Berliner, Nancy
    Wickerham, D. Lawrence
    Wolmark, Norman
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (13): : 904 - 910
  • [3] Factor V leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen.
    Garber, JE
    Halabi, S
    Kaplan, E
    Edge, S
    Dressler, L
    Paskett, E
    Berliner, N
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 6S - 6S
  • [4] Correlation of factor V G20210A (Leiden), prothrombin G20210A, and MTHFR C677T with thromboembolic events in the Lebanese population
    Irani-Hakime, N
    Samaha, H
    Dacchache, J
    Rahal, E
    EUROMEDLAB 2003: PROCEEDINGS OF THE 15TH IFCC-FESCC EUROPEAN CONGRESS OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, : 481 - 486
  • [5] Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage
    Reznikoff-Etiévant, MF
    Cayol, V
    Carbonne, B
    Robert, A
    Coulet, F
    Milliez, J
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2001, 108 (12): : 1251 - 1254
  • [6] Breast cancer prevention: results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) breast cancer prevention trial (NSABP P-1: BCPT)
    Dunn, BK
    Ford, LG
    EUROPEAN JOURNAL OF CANCER, 2000, 36 : S49 - S50
  • [7] Prothrombin G20210A variant, resistance to activated protein C (APC) and factor V Leiden (FVL) in patients with colorectal cancer.
    Paspatis, GA
    Sfyridaki, A
    Papanikolaou, N
    Kapsoritakis, A
    Triantafyllou, K
    Livadiotaki, A
    Kissamitaki, V
    GASTROENTEROLOGY, 2001, 120 (05) : A292 - A292
  • [8] Factor V Leiden and prothrombin 20210 G-A mutations in controls and in patients with thromboembolic events during pregnancy or the puerperium
    Mehmet Yilmazer
    Gulay Kurtay
    Murat Sonmezer
    Nejat Akar
    Archives of Gynecology and Obstetrics, 2003, 268 (4) : 304 - 308
  • [9] Factor V Leiden and prothrombin G20210A polymorphisms are not associated with disease-free survival in breast cancer
    Aydan Eroglu
    Ragip Çam
    Yonca Eğin
    Nejat Akar
    Breast Cancer Research and Treatment, 2009, 116 : 619 - 620
  • [10] Factor V Leiden and prothrombin G20210A polymorphisms are not associated with disease-free survival in breast cancer
    Eroglu, Aydan
    Cam, Ragip
    Egin, Yonca
    Akar, Nejat
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 116 (03) : 619 - 620
123